Severn, MD, United States of America

Antonette C P Allen


Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2004

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Antonette C P Allen in Genetic Research

Introduction: Antonette C P Allen, based in Severn, MD, is a distinguished inventor known for his significant contributions to genetic research. His work has particularly focused on enhancing the understanding of the BRCA1 gene and its implications for breast and ovarian cancer susceptibility.

Latest Patents: Allen holds a patent for the coding sequence haplotype of the human BRCA1 gene. This invention involves isolated coding sequences and the respective protein sequences they encode. Specifically, the patent introduces the BRCA1(omi4) sequence, which is instrumental in identifying individuals who possess an increased genetic risk due to inherited mutations in their BRCA1 gene. Furthermore, the invention extends to methods for gene therapy utilizing the isolated BRCA1(omi4) coding sequence and protein replacement therapy with the corresponding BRCA1(omi4) protein.

Career Highlights: Allen has significantly impacted the field during his career at Gene Logic, Inc., where he has dedicated his efforts to research and development in genetics. His innovative approaches have paved the way for advancements in cancer therapies and understanding hereditary diseases.

Collaborations: Throughout his career, Antonette has collaborated with colleagues such as Tracy Staton Angelly and Tammy Lawrence, working together to drive forward the frontiers of genetic research. These collaborations highlight the importance of teamwork in achieving breakthroughs in scientific endeavors.

Conclusion: Antonette C P Allen is a noteworthy inventor whose work on the BRCA1 gene has substantial implications for the realm of genetic research and therapy. His contributions have not only enriched academic knowledge but also offered potential avenues for improving patient outcomes in the fight against breast and ovarian cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…